https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50150 50% at baseline). Untargeted gas chromatography–mass spectrometry analysis was performed to analyse baseline levels of 68 serum metabolites. Of the nine metabolites that differentiated placebo and NAC groups, five were amino acids with lower levels in the NAC responder group compared with the NAC non-responders. Further analysis generated a predictive model of MADRS improvement including glycine, norleucine, threonine, proline, phenylalanine, tyrosine, glutamic acid, lysine and leucine (R2 = 0.853; adjusted R2 = 0.733). This prediction model predicted 85% of the variance in MADRS outcome after adjunctive treatment with NAC. BD participants with lower serum levels of free amino acids at baseline may be more likely to respond to adjunctive treatment with NAC.]]> Wed 05 Jul 2023 14:11:36 AEST ]]> Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49523 Sat 20 May 2023 12:39:02 AEST ]]> The effect of adjunctive mangosteen pericarp on cognition in people with schizophrenia: secondary analysis of a randomized controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45466 n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.]]> Fri 28 Oct 2022 14:45:19 AEDT ]]> Exploring interleukin-6, lipopolysaccharide binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51700 Fri 15 Sep 2023 10:39:15 AEST ]]>